乳腺癌治疗时间间隔：基于人群的研究，探讨了就诊癌症中心的类型和数量的影响。
Treatment time interval in breast cancer: A population-based study on the impact of type and number of cancer centres attended.
机构信息
CERPOP, Université de Toulouse, Inserm, UPS, Toulouse, France.
Equipe labélisée LIGUE Contre le cancer, Faculté de Médecine, UMR 1295 Inserm, Toulouse, France.
出版信息
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13654. doi: 10.1111/ecc.13654. Epub 2022 Jul 22.
OBJECTIVES
We studied both the independent and combined effects of the places of biopsy and treatment on the treatment time interval based on a population-based study.
METHODS
We analysed the proportion of patients having a treatment time interval higher than the EUSOMA recommendation of 6 weeks, as a function of the number and the type of care centres the patients attended, from a French population-based regional cohort of women treated in 2015 for an incident invasive non-metastatic cancer (n = 505).
RESULTS
About 33% [95% CI: 27; 38] of patients had a treatment time interval higher than 6 weeks. About 48% of the patients underwent their biopsy and their initial treatment in the different centres. Results from multivariable analyses supported the impact of the type and number of centres attended on the proportion of time intervals over 6 weeks. This proportion was higher among patients with biopsy and treatment in different centres and among patients treated in a university hospital.
CONCLUSION
We pointed out the independent impact of the type and the number of care centres the patients attended, from biopsy to first treatment, on the treatment time interval, which is a well-known prognosis factor.
目的
我们基于一项基于人群的研究，研究了活检部位和治疗部位对治疗时间间隔的独立和联合影响。
方法
我们分析了 2015 年接受新诊断侵袭性非转移性癌症治疗的法国女性（n=505）中，根据患者就诊的医疗中心数量和类型，治疗时间间隔超过 EUSOMA 推荐的 6 周的患者比例。
结果
约 33%（95%CI：27；38）的患者治疗时间间隔超过 6 周。约 48%的患者在不同的中心进行了活检和初始治疗。多变量分析的结果支持了所就诊的医疗中心类型和数量对超过 6 周时间间隔比例的影响。在活检和治疗在不同中心进行的患者以及在大学医院治疗的患者中，这一比例更高。
结论
我们指出了患者从活检到首次治疗期间就诊的医疗中心类型和数量对治疗时间间隔的独立影响，而治疗时间间隔是一个众所周知的预后因素。
Zotero 插件